In a trial involving 76 Parkinson’s patients, dipraglurant showed a statistically significant reduction in the involuntary movements linked with the most widely used drug to treat the disease, Geneva-based Addex said in a statement after the close of trading today.
The drug also met its safety targets in the trial, Addex said.
Addex said today it’s changing its name to Addex Therapeutics. The switch has to be approved by shareholders.
To contact the reporter on this story: Simeon Bennett in Geneva at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org